Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2022

The Pharma Closeout tracks 56 deals, $152.3B in disclosed deal value, 22 with a post-close Outcome Score for the year 2022.

Median Critic Score: 83  ·  Median Outcome Score: 62

Best outcome: Merck & Co. Inc. / Moderna, Inc. (86)  ·  Weakest outcome: Pfizer Inc. / Global Blood Therapeutics Inc. (29)

All 56 deals

• Merck & Co. Inc. / Moderna, Inc. — 2022 · $250M · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi — 2022 · $6.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Abiomed Inc. — 2022 · $16.6B · Largely worked — most objectives met.
• Amgen Inc. / Horizon Therapeutics plc — 2022 · $27.8B · Largely worked — most objectives met.
• Biocon Biologics Ltd. / Viatris Biosimilars Business — 2022 · $3.0B · Largely worked — most objectives met.
• GSK plc / Sierra Oncology Inc. — 2022 · $1.9B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. — 2022 · $4.1B · Largely worked — most objectives met.
• Pfizer Inc. / Biohaven Pharmaceutical Holding Company Ltd. — 2022 · $11.6B · Largely worked — most objectives met.
• Roche Holding AG / Repare Therapeutics Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Largely worked — most objectives met.
• Pfizer Inc. / Beam Therapeutics Inc. — 2022 · $1.4B · Largely worked — most objectives met.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• Amgen Inc. / ChemoCentryx Inc. — 2022 · $3.7B · Largely worked — most objectives met.
• Vertex Pharmaceuticals Inc. / ViaCyte Inc. — 2022 · $320M · Largely worked — most objectives met.
• Merck & Co. Inc. / Imago BioSciences Inc. — 2022 · $1.4B · Largely worked — most objectives met.
• Merck & Co. Inc. / Kelun-Biotech Biopharmaceuticals Co. Ltd. — 2022 · $936M · Largely worked — most objectives met.
• Sumitovant Biopharma / Myovant Sciences — 2022 · $1.7B · Largely worked — most objectives met.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Mixed — partial payoff, real shortfalls.
• Viatris / Oyster Point Pharma, Inc. — 2022 · $299M · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Mixed — partial payoff, real shortfalls.
• GSK plc / Affinivax Inc. — 2022 · $3.3B · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / Global Blood Therapeutics Inc. — 2022 · $5.4B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Nimbus Therapeutics (Lakshmi subsidiary, TYK2 program) — 2022 · $6.0B
• Recordati S.p.A. / EUSA Pharma (UK) Ltd. — 2022 · $845M
• Bristol-Myers Squibb Company / Century Therapeutics Inc. — 2022 · $3.1B
• Bristol-Myers Squibb Company / Immatics N.V. — 2022 · $770M
• Sanofi SA / Exscientia plc — 2022 · $5.3B
• AstraZeneca PLC (Alexion) / LogicBio Therapeutics Inc. — 2022 · $70M
• Sanofi SA / Innate Pharma SA — 2022 · $1.4B
• Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) — 2022 · $1.1B
• Merck & Co. Inc. / Moderna Inc. (mRNA-4157/V940 option exercise) — 2022 · $250M
• Sumitomo Pharma / Sumitovant Biopharma / Myovant Sciences Ltd. — 2022 · $1.7B
• ABL Bio Inc. / Sanofi S.A. (ABL301 license to Sanofi) — 2022 · $1.1B
• AbbVie Inc. / DJS Antibodies Ltd. — 2022 · $255M
• Roche Holding AG / Poseida Therapeutics Inc. — 2022 · $6.1B
• Sanofi SA / IGM Biosciences Inc. — 2022 · $6.2B
• Sanofi SA / Adagene Inc. — 2022 · $2.5B
• AstraZeneca PLC / Neogene Therapeutics B.V. — 2022 · $320M
• Eli Lilly and Company / Nimbus Therapeutics LLC — 2022 · $496M
• UCB S.A. / Zogenix Inc. — 2022 · $1.9B
• Novartis AG / Voyager Therapeutics Inc. — 2022 · $1.8B
• Pfizer Inc. / Valneva SE (VLA15 collaboration update) — 2022 · $363M
• Sanofi SA / Atomwise Inc. — 2022 · $1.0B
• Bayer AG / Mammoth Biosciences Inc. — 2022 · $1.0B
• AbbVie Inc. / Sosei Group Corp. (Sosei Heptares) — 2022 · $1.3B
• Eli Lilly and Company / Sosei Group Corp. (Sosei Heptares) — 2022 · $730M
• GSK plc / Spero Therapeutics, Inc. — 2022 · $600M
• Blackstone Life Sciences / Sanofi S.A. (Sarclisa subQ co-development) — 2022 · $331M
• Sanofi SA / Skyhawk Therapeutics Inc. — 2022 · $2.1B
• Sanofi SA / Insilico Medicine Inc. — 2022 · $1.2B
• AstraZeneca PLC (Alexion) / Neurimmune AG (NI006 license) — 2022 · $760M
• Pfizer Inc. / ReViral Ltd. — 2022 · $525M
• AbbVie Inc. / Syndesi Therapeutics SA — 2022 · $1.0B
• Merck & Co. Inc. / Orna Therapeutics, Inc. — 2022 · $3.6B
• Ipsen S.A. / Epizyme Inc. — 2022 · $247M
• Eli Lilly and Company / Akouos Inc. — 2022 · $610M

← Deal Library  ·  Interactive search  ·  How we score deals